Letermovir in pregnancy versus valaciclovir for fetal CMV
Treatments studied
Part of Genetic & congenital, Infections, Women’s health & pregnancy clinical trials.
This trial tests whether letermovir can treat a baby’s early (first-trimester) congenital CMV infection in pregnancy, compared with the standard drug valaciclovir. The goal is to reduce serious effects from CMV while monitoring safety and pregnancy outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and at least 18 years old
- You were infected with CMV early in pregnancy (first trimester)
- Between 15 and 28 weeks, testing from amniotic fluid shows CMV (positive CMV PCR)
- Your ultrasound does not show certain severe brain changes (like enlarged ventricles, hydrocephalus, or very small head size)
- You can give consent and are able and willing to attend study visits and tests
- You have health insurance coverage through a social security plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This Phase 2 trial tests whether the medicine letermovir can prevent a common viral infection (CMV) after a new heart transplant. It may help reduce CMV infection or illness in people who are at moderate to high CMV risk.
This study compares a new antiviral drug (letermovir) to a standard one (valganciclovir) for preventing CMV infection after lung transplant. It is for people who are at high risk because the donor had CMV but the recipient did not.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
This study tests a drug called letermovir to prevent CMV infection after a kidney or liver transplant. It is for adults at moderate risk of CMV and may help keep you healthy after surgery.
Hear when a new Pregnant Women trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.